EUVIMEDEUVIMED entdecken
Crossref

Abstract 1364: Neuroguard Integrated Embolic Protection System for Carotid Artery Stenting: An Early Single-Center Experience at a Tertiary Center.

C. A. Nwogu, X. Lor, C. Richardson, D. Patel, S. Patel, F. O. Otite

Stroke: Vascular and Interventional Neurology · 18.10.2026 · 6 (Suppl_1)

DOI: 10.1161/svi270000_1364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke: Vascular and Interventional Neurology, erschienen am 18.10.2026. Verfasst von C. A. Nwogu und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Neuroguard IEP (Integrated Embolic Protection) system (Contego Medical, distributed by Medtronic) is a novel 3-in-1 carotid artery stenting (CAS) device that combines a nitinol closed-cell stent with FlexRing technology, an integrated post-dilation balloon, and a 40-micron embolic protection filter within a single catheter system. This study aimed to assess the feasibility and safety of the Neuroguard IEP system at a single tertiary care center.

Methods

This was a single-center retrospective study describing consecutive patients who underwent CAS using the Neuroguard IEP system at a single center in the United States. Technical feasibility and safety were assessed in terms of intra- and postprocedural complications, as well as neurological morbidity upon discharge and follow-up.

Results

We included 36 procedures in 34 patients (mean age 72.0 ± 9.9 years; male: 29/36, 80.6%). Two-thirds of patients (66.7%) were symptomatic prior to intervention. There was a 100% technical success rate with zero distal embolization events. No primary outcomes occurred — there were no periprocedural strokes, hemorrhagic events, or myocardial infarctions. Two non-periprocedural, all-cause deaths were recorded (5.6%). Post-24-hour hemodynamic instability (hypotension or bradycardia) occurred in 9 cases (25.0%). At discharge, 77.8% of patients had a favorable modified Rankin Scale (mRS) of 0-2. At follow-up, all 26 patients who underwent carotid duplex ultrasound had a patent stent.

Conclusions

The use of the Neuroguard IEP may be technically feasible and safe in symptomatic and asymptomatic CAS.

Zitieren

APA

Nwogu, C. A., Lor, X., Richardson, C., Patel, D., Patel, S., & Otite, F. O. (2026). Abstract 1364: Neuroguard Integrated Embolic Protection System for Carotid Artery Stenting: An Early Single-Center Experience at a Tertiary Center. Stroke: Vascular and Interventional Neurology, 6(Suppl_1). https://doi.org/10.1161/svi270000_1364

Vancouver

Nwogu CA, Lor X, Richardson C, Patel D, Patel S, Otite FO. Abstract 1364: Neuroguard Integrated Embolic Protection System for Carotid Artery Stenting: An Early Single-Center Experience at a Tertiary Center. Stroke: Vascular and Interventional Neurology. 2026;6(Suppl_1). doi:10.1161/svi270000_1364

BibTeX
@article{Nwogu2026,
  author = {Nwogu, C. A. and Lor, X. and Richardson, C. and Patel, D. and Patel, S. and Otite, F. O.},
  title = {Abstract 1364: Neuroguard Integrated Embolic Protection System for Carotid Artery Stenting: An Early Single-Center Experience at a Tertiary Center},
  journal = {Stroke: Vascular and Interventional Neurology},
  year = {2026},
  volume = {6},
  number = {Suppl_1},
  doi = {10.1161/svi270000_1364}
}
Kostenlos starten →